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Background: The relationship between the SYNTAX score (SS) and stent
thrombosis (ST) has not been described. We therefore examined the relationship
between SS and ST in high-risk patients with non-ST-segment elevation acute
coronary syndromes (NSTE-ACS) pts undergoing percutaneous coronary inter-
vention (PCI).
Methods:We stratiﬁed 2,627 pts from the ACUITY-PCI cohort by SS tertile distribution
(in ACUITY: SS <7 (n¼854), SS 7-12 (n¼825), and SS >12 (n¼948); and from the
original SYNTAX trial: SS<23 (n¼ 2315), SS 23-32 (n¼248), and SS >32 (n¼ 64)).
Thirty-day and 1-year rates of ARC deﬁnite/probable ST were determined for each SS
tertile.
Results: A total 30 and 41 deﬁnite/probable STs occurred at 30 days and 1 year
respectively. When stratiﬁed by ACUITY tertiles, 30-day and 1-year rates of deﬁnite/
probable ST were signiﬁcantly greater in the highest tertile (SS>12, 2.0% and 2.8%)
compared with the intermediate (SS7-12, 0.7% and 1.1%) and lowest tertiles (SS<12,
0.6% and 0.7%), p¼0.007 and p¼0.0009, respectively. When stratiﬁed by original
SYNTAX tertiles, 30-day and 1-year rates of deﬁnite/probable ST were signiﬁcantly
greater in the highest (SS>32, 6.3% and 8.8%) and intermediate groups (SS23-32,
2.8% and 3.7%) compared with the lowest group (SS<22, 0.8% and 1.2%), p
<0.0001 and p <0.0001, respectively. After multivariable adjustment for clinical
differences between groups, SS (per 1 point increase) remained an independent
predictor of both 30-day (hazard ratio [HR], 1.06; 95% conﬁdence interval [CI] 1.03
to 1.09; p¼0.0002) and 1-year (HR, 1.06; 95% CI, 1.03 to1.09; p<0.0001) deﬁnite/
probable ST.
Conclusions: In NSTE-ACS pts treated by PCI, the extent of severity of CAD, as
assessed by the baseline SS, was strongly associated with the occurrence of ST both at
30 days and 1 year.Table 3. 30-Days and 1-Year Rates of ST Stratiﬁed by True Tertiles and Orig-
inal SYNTAX Tertiles
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30-Day ST
Deﬁnite
thrombosis
3 (0.4) 3 (0.4) 11 (1.2) 0.04 0.97 0.05 0.057
Deﬁnite/
probable
thrombosis
5 (0.6) 6 (0.7) 19 (2.0) 0.007 0.72 0.008 0.02
1-Year ST
Deﬁnite
thrombosis
4 (0.5) 6 (0.7) 16 (1.8) 0.02 0.49 0.01 0.06
Deﬁnite/
probable
thrombosis
6 (0.7) 9 (1.1) 26 (2.8) 0.0009 0.40 0.001 0.01
Original
SYNTAX
Tertiles
Tertile I
(N[2315)
Tertile II
(N[248)
Tertile III
(N[64)
Overall
p-Value
p-Value
I vs. II
p-Value I
vs. III
p Value II
vs. III
30-Day ST
Deﬁnite
thrombosis
12 (0.5) 3 (1.2) 2 (3.2) 0.01 0.17 0.006 0.27
Deﬁnite/
probable
thrombosis
19 (0.8) 7 (2.8) 4 (6.3) <0.0001 0.002 <0.0001 0.17
1-Year ST
Deﬁnite
thrombosis
19 (0.8) 4 (1.6) 3 (5.8) 0.003 0.20 0.001 0.13
Deﬁnite/
probable
thrombosis
27 (1.2) 9 (3.7) 5 (8.8) <0.0001 0.001 <0.0001 0.13
Data presented as n (%); True tertiles<7, 7-12,>12; Original SYNTAX tertile <23,23-32,>32;
ST ¼ stent thrombosis
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Can in-stent neointimal characteristics predict late neointimal progression after
drug-eluting stent implantation?: a serial optical coherence tomography study
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Background: Progressive neointimal proliferation leads to late restenosis and/or
neoatherosclerosis after drug-eluting stent (DES) implantation. Late neointimal
response may be different among different tissue components.The aim of this study
was to assess impact of in-stent neointimal characteristics on late neointimal prolif-
eration following DES implantation.
Methods: Serial (at 12 and 18 months after DES implantation) optical coherence
tomography (OCT) imaging was performed in 26 stented lesions. In-stent neointima
was categorized as either homogeneous (Homo) or heterogeneous (Hetero) pattern
based on the OCT appearance. Serial changes in % neointimal area (%NIA¼ neo-
intimal area / stent area x 100) were compared between lesions with Homo and
Hetero.
Results: At 12 months, Homo was observed in 10 (38%) and Hetero in 16 (62%)
lesions. During follow-up, NIA in lesions with Homo decreased signiﬁcantly (1.9 
0.94/1.60.94mm2, P¼0.003). On the other hand, NIA in lesions with Hetero did
not change signiﬁcantly (2.71.8/2.61.5mm2, P¼0.877). Late neointimal
progression (NIA at 18 months - NIA at 12 months > 0) was observed in 1 of 10
(10%) lesions with Homo and in 9 of 16 (56%) lesions with Hetero.
Conclusions: OCT characteristics of neointima after DES implantation may predict
late neointimal progression or regression.
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Background: Dual antiplatelet therapy (DAPT), consisting of aspirin plus a thieno-
pyridine, is currently recommended for 6 to 12 months following drug-eluting stent
implantation. We previously reported a low risk of stent thrombosis (ST) in the ﬁrst
year after Resolute Zotarolimus-eluting stent (R-ZES) placement among patients in
whom DAPT was interrupted or discontinued beyond the ﬁrst month post-procedure.
We sought to examine the longer term impact of early DAPT discontinuation as well
as the impact of later DAPT discontinuation on subsequent clinical outcomes.
Methods: All patients with 3-year ST data (n¼4,896) treated with a R-ZES in the global
RESOLUTE clinical programwere analyzed according to DAPT status. STwas assessed
basedon the timing ofﬁrstDAPT interruption (0-1,>1-12,>12-24 and>24-36months),
which was deﬁned as an interruption of either aspirin or thienopyridine >14 days.
Results: Baseline characteristics of all patients with a >14 day DAPT interruption
included age 66 years, 32% with diabetes and 41% with an acute coronary syndrome.
A total of 50 ST events occurred through 3 years after R-ZES; 29 (58%) of these
events were within 1 month of stent placement regardless of DAPT status. The
number (%) of events in each interruption period is shown in the ﬁgure.Conclusions: For patients with a >14 day DAPT interruption after 1 month, the
occurrence of subsequent ST remained low through 3 years following R-ZES
implantation. These data underscore the necessity of additional prospective data in
order to determine the optimal duration of DAPT after DES implantation.acts/POSTER/In-stent Restenosis and Stent Thrombosis B143
